A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI